ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag stock market immunology neuroscience

Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
Will Wall Street's Love Affair With Biotech Continue?
Susan L-J Dickinson | May 26, 1991 | 7 min read
As more companies prove themselves with products and profits, biotech stocks continue to surge Early last month, three-year-old Regeneron Pharmaceuticals Inc. shook the business world by raising $99 million--nearly double what the company had originally planned to raise--in its initial public stock offering. The deal was remarkable for two reasons. The amount of money raised in this IPO was second in the biotech community only to that of Cetus Corp., of Emeryville, Calif., which raised $115 mi
a mockup of an at-home COVID-19 test in development
Top Technical Advances of 2020
Shawna Williams | Dec 18, 2020 | 3 min read
The pandemic spurred innovation in a variety of ways, from CRISPR-based diagnostics to cell biology benchwork at home.
Despite Chill Winds On Wall Street, Investors Continue To Place Bets On Fledgling Biotechnology Companies
Scott Veggeberg | Apr 4, 1993 | 10+ min read
Stock market declines have taken their toll on established firms, but startup ventures still attract backing Launching a new biotechnology company calls for a number of key ingredients, as any wide-eyed scientist who has tested the entrepreneurial waters will attest. You need your enlightened concept, of course, and the enduring visionary force that eventually is to hammer your concept into shape as a viable product. You also need the right people--and the proper blend of them--to keep the
Italian Company Seeks Foothold In U.S. Science
Jules Asher | Jan 7, 1990 | 9 min read
With a neuroscience institute in Washington and an emphasis on basic research, FIDIA aims to bolster respect worldwide WASHINGTON - Long after the vinyl and paper folders from a typical scientific conference have been tossed in the trash, a genuine imported leather portfolio with bright red decorative stitching and the inscription: "FIDIA-Georgetown Institute for the Neurosciences, November 3, 1985" is likely to remain on the shelves of many scientists. It's just too nice to throw away. That
2020 Top 10 Innovations
The Scientist | Dec 1, 2020 | 10+ min read
From a rapid molecular test for COVID-19 to tools that can characterize the antibodies produced in the plasma of patients recovering from the disease, this year’s winners reflect the research community’s shared focus in a challenging year.
Biotech Industry Gearing Up For More Science, Less Hype
Franklin Hoke | Jun 21, 1992 | 6 min read
But it's still unclear which new approaches in human therapeutics will pay off big; cancer and neuroscience are among the contenders Despite the enormous amount of money invested in research and development of biotechnology-derived human therapeutics in the past two decades or so, biotech industry participants and observers say the future is still unclear. Only 21 biotech drugs have been released so far, and many of those are bioengineered versions of substances that have been known and used
2018 Top 10 Innovations
The Scientist | Dec 1, 2018 | 10+ min read
Biology happens on many levels, from ecosystems to electron transport chains. These tools may help spur discoveries at all of life's scales.
Biotech Firms Spot Opportunity As Baby-Boomer Generation Ages
Karen Young Kreeger | Feb 18, 1996 | 8 min read
Generation Ages Author: Karen Young Kreeger Date: February 19, 1996 As the baby-boomer generation gets older, biotech companies are stepping up their research efforts with the goal of capitalizing on the huge potential market for anti-aging products. The number of drugs and therapies in development for diseases of the elderly increased from 125 in 1993 to 132 in July 1995. The number of companies developing those remedies climbed from 60 to 71 in the same time frame, according to New Medicines
Molecular Multitasking
Carina Storrs | Aug 1, 2013 | 6 min read
Commercial kits use fluorescent beads to probe dozens of cytokines in one reaction.

Run a Search

ADVERTISEMENT